PuraPharm Corp. Ltd. (HK:1498)
:1498
Top Page
PuraPharm Corp. Ltd.
(1498)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$0.34
▼(-4.00% Downside)
Action:ReiteratedDate:11/26/25
The overall score of 42 reflects significant concerns with PuraPharm's financial health, driven by declining revenue, ongoing losses, and high debt levels, despite positive cash flow growth. Technical indicators further weigh on the score with bearish trends, while valuation remains uncertain due to negative earnings.
Positive Factors
Improved Cash Flow
Growth in free cash flow suggests improved capital management and operational efficiency, enhancing the company's ability to invest in growth opportunities.
Negative Factors
Profit Warning
The profit warning indicates ongoing financial difficulties, with rising costs and market challenges affecting profitability and long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Cash Flow
Growth in free cash flow suggests improved capital management and operational efficiency, enhancing the company's ability to invest in growth opportunities.
Read all positive factors
PuraPharm Corp. Ltd. (1498) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$163.16M
Dividend YieldN/A
Average Volume (3M)128.80K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-17.32%
EPS Growth55.74%
CountryHK
Employees479
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.03
Shares Outstanding535,897,640
10 Day Avg. Volume96,100
30 Day Avg. Volume128,800
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.95
Price to Sales (P/S)0.57
P/FCF Ratio2.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PuraPharm Corp. Ltd. Business Overview & Revenue Model
Company Description
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates thr...
How the Company Makes Money
PuraPharm Corp. Ltd. generates revenue primarily through the sale of its TCM products, including herbal formulations and dietary supplements. The company's revenue model is based on direct sales to consumers, as well as distribution through pharma...
PuraPharm Corp. Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
20
Very Negative
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 346.76M | 382.09M | 406.86M | 448.07M | 659.59M | 601.82M |
| Gross Profit | 187.00M | 205.14M | 216.63M | 260.59M | 421.85M | 368.69M |
| EBITDA | 10.45M | 17.35M | -26.31M | -46.34M | -40.03M | 114.67M |
| Net Income | -38.56M | -35.44M | -106.08M | -120.21M | -121.88M | 31.71M |
Balance Sheet | ||||||
| Total Assets | 678.76M | 715.73M | 843.96M | 1.02B | 1.21B | 1.37B |
| Cash, Cash Equivalents and Short-Term Investments | 49.89M | 12.79M | 47.22M | 91.36M | 85.05M | 126.46M |
| Total Debt | 374.45M | 363.76M | 424.77M | 503.16M | 531.96M | 524.11M |
| Total Liabilities | 577.10M | 604.53M | 690.73M | 757.18M | 803.13M | 859.07M |
| Stockholders Equity | 101.66M | 111.20M | 153.24M | 258.29M | 401.56M | 511.66M |
Cash Flow | ||||||
| Free Cash Flow | 78.85M | 89.18M | 57.95M | 42.29M | -45.89M | 3.84M |
| Operating Cash Flow | 92.78M | 103.98M | 79.61M | 65.85M | -39.33M | 86.68M |
| Investing Cash Flow | -5.66M | -11.71M | -18.20M | -25.45M | 6.00M | -92.11M |
| Financing Cash Flow | -72.29M | -86.43M | -122.39M | -12.94M | -13.87M | -3.61M |
PuraPharm Corp. Ltd. Technical Analysis
Negative
0.35
Price Trends
0.33
Negative
0.35
Negative
0.40
Negative
Market Momentum
>-0.01
Positive
32.11
Neutral
42.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1498, the sentiment is Negative. The current price of 0.35 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.33, and below the 200-day MA of 0.40, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.11 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1498.
PuraPharm Corp. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$211.65M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$926.38M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
48 Neutral | HK$683.28M | -17.91 | 20.98% | ― | ― | ― | |
48 Neutral | HK$177.84M | -40.12 | -8.95% | ― | 2.54% | 33.33% | |
44 Neutral | HK$167.36M | -0.14 | -43.61% | ― | 6.55% | -475.22% | |
42 Neutral | HK$163.16M | -4.22 | -30.35% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.21
-40.20%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
0.04
76.60%
HK:1011
China NT Pharma Group Co., Ltd.
0.72
0.50
227.27%
HK:1312
Kontafarma China Holdings Ltd
0.03
<0.01
25.00%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.26
1.02
425.00%
HK:8622
Huakang Biomedical Holdings Company Limited
0.35
0.04
15.00%
PuraPharm Corp. Ltd. Corporate Events
PuraPharm Announces Board Composition and Roles
Oct 30, 2025
PuraPharm Corporation Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement provides clarity on the governance structure of the company, which could impact its strategi...
PuraPharm Completes Key Share Transactions to Enhance Market Position
Oct 30, 2025
PuraPharm Corporation Limited announced the completion of a Patent Licence Agreement and a Subscription Agreement, both involving the issuance of new shares. Under the Patent Licence Agreement, 93,488,372 Consideration Shares were issued, represen...
PuraPharm Appoints Experienced Finance Professional as Non-Executive Director
Oct 30, 2025
PuraPharm Corporation Limited has announced the appointment of Mr. Dong Zimeng as a non-executive director effective from October 30, 2025. Mr. Dong brings 17 years of experience in finance, capital market investment, mergers and acquisitions, and...
PuraPharm Shareholders Approve Key Resolutions at EGM
Oct 24, 2025
PuraPharm Corporation Limited announced that during their extraordinary general meeting held on October 24, 2025, shareholders approved two key resolutions. These resolutions included the ratification of a Patent Licence Agreement and the issuance...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.